TrialHuman vaccines & immunotherapeutics2018

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial.

Shrikant Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.